Basic Aspects of Tumor Immunology

Organizer(s): Nicholas P. Restifo and Nina Bhardwaj

Sponsored in part by The Director's Sponsor Fund

For important information on the coronavirus, please click here

Summary of Meeting:

The past decade has seen great strides in the field of tumor immunology. High avidity CD8+ and CD4+ T cells from the available human T cell repertoire have been used to identify a large number of tumor-associated antigens. We have devised immunization strategies that enable us to boost immune responses against these antigens and some encouraging, but preliminary, results have been obtained in the clinic. Despite much excitement, these advances have not yet led to reproducibly effective cancer treatments. The challenge now is to gain a deeper understanding of how immune cells interact with and potentially destroy tumor cells. This meeting will bring together experts from academia and industry in an effort to elucidate the basic immunology that could make it possible to trigger and sustain an immune response capable of mediating the complete destruction of tumor cells.

Discounted Abstract Deadline: October 17 2002

Discounted Registration Deadline: December 17 2002

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations